Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer

This is a randomized, controlled, multicenter clinical study that enrolled patients with unresectable bulky stage III NSCLC, with PFS as the primary endpoint. The study aims to investigate the efficacy and safety of adebrelimab combined with chemoradiotherapy in the treatment of locally advanced/unresectable stage III non-small cell lung cancer.

NCT Number	NCT07560358
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment	204 participants
Start Date	2026-05-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-01